The long-term trend of the EPS is an important number as it indicates the present value of Invitae Corporation. It is usually expressed as a percentage and is then referred to as the EPS growth rate, which at this time is hard to estimate, but revenue growth has been 72.20 % over the last twelve months. EPS growth is a vital measure of execution of the strategy for Invitae Corporation since it indicates how well the business is allocating resources to benefit shareholders.

Invitae Corporation is part of the medical diagnostics and research industry and healthcare sector. The company CEO is Sean E. George. Invitae Corp is a genetic information company engaged in genetic diagnostics for hereditary disorders. It provides testing for multiple genes including hereditary cancer, neurological disorders, cardiovascular disorders and other hereditary conditions.

Previous Intraday Performance:

The NVTA shares had a previous change of -8.64% which opened at 14.33 and closed at 13.22. It moved to an intraday high of 14.71 and a low of 13.07.

SeekingAlpha:  FDA nod for Loxo’s larotrectinib a positive for cancer genetic testing providers

Historical Performance:

Over the last five trading days, NVTA shares returned -5.57% and in the past 30 trading days it returned 1.61%. Over three months, it changed -7.23%. In one year it has changed 55.71% and within that year its 52-week high was 18.38 and its 52-week low was 4.35. NVTA stock is 203.91% above its 52 Week Low.

Our calculations result in a 200 day moving average of 9.72 and a 50 day moving average of 13.88. Right now, NVTA stock is trading 36.01% above its 200 day moving average.

SeekingAlpha:  FDA nod for Loxo’s larotrectinib a positive for cancer genetic testing providers


The company has a market cap of $991.4m with 75.0m shares outstanding and a float of 70.0m shares. Trading volume was 793,401 shares and has experienced an average volume of 1,076,714 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.


The last annual reported EPS for Invitae Corporation was -2.66 which ended on 31st of December 2017. Based on 3 analyst estimates, the consensus EPS for the next quarter is -0.47.

Below was the last reported quarterly earnings per share:
09-30-2018:  -0.45
06-30-2018:  -0.47
03-31-2018:  -0.66
12-31-2017:  -0.78

Indicators Also to Watch:

Based on the latest filings, there is 87.00% of institutional ownership. Short-interest was 2,704,577, which was 3.61% of shares outstanding. The short-interest ratio or days-to-cover ratio was 2.41. This stock has some short interest, but it might be normal and no need to worry if long the position.

I calculated the beta to be 1.80

Business Wire:  CORRECTING and REPLACING Ocular Therapeutix(TM) Announces FDA Approval of DEXTENZA® for the Treatment of Ocular Pain Following Ophthalmic Surgery

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -92.26%, return on assets is -56.52%, price-to-sales is 8.65 and price-to-book is 5.53.

Company Score Card:

Results are out of six:
 2  : Growth Expectations Result
 5  : Financial Safety Result
 0  : Past Performance Result
 0  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).


Please enter your comment!
Please enter your name here